Abstract
Background Previous observational and Mendelian randomization studies suggested different amino acids associated with type 2 diabetes (T2D). However, these studies may suffer from confounding or the use of invalid instruments, respectively.
Methods We extracted strong (p < 5×10-8), independent (r2 < 0.001) genetic variants associated with nine amino acids (alanine, glutamine, glycine, histidine, phenylalanine, tyrosine, isoleucine, leucine, and valine) from summary statistics of UK Biobank (N ≤ 115,075), with exclusion of potentially pleiotropic variants. We then applied them to T2D summary statistics from DIAMANTE Consortium (without UK Biobank participants) (N = 455,313) and FinnGen study (N = 365,950), and glycemic traits (MAGIC consortium, N ≤ 209,605). Inverse variance weighed (IVW) method was the main analysis, with multiple sensitivity analyses to assess robustness of findings.
Results Alanine was associated with higher T2D risk, correcting for multiple testing (Odds Ratio (OR) 1.50 per SD; 95% CI 1.16 to 1.95). At nominal significance, isoleucine was associated with higher T2D risk (OR 1.13; 95% CI 1.00 to 1.27) and tyrosine was associated with lower T2D risk (OR 0.89; 95% CI 0.80 to 0.99). Alanine was also associated with lower insulin, higher glycated hemoglobin and glucose whereas isoleucine and leucine were associated with lower insulin. These associations were consistent in most sensitivity analyses.
Conclusion Alaine likely contributed to higher T2D risk whilst the associations for isoleucine and tyrosine requires further verification. Whether these findings explain health effects of sources of amino acids, such as diet, should be further explored.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partly funded by the Health and Medical Research Fund, Health Bureau, Hong Kong Special Administrative Region, China (CFS-HKU-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study only used publicly available summary data and hence no ethics approval is required. Details of ethical approval and participant consent for each of the studies that contributed to the GWAS can be found in the original publications.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The summary statistics of NMR metabolites are available on IEU GWAS database (https://gwas.mrcieu.ac.uk/datasets/?gwas_id__icontains=met-d). The summary statistics for T2D of DIAMANTE consortium and FinnGen study are available on (https://diagram-consortium.org/downloads.html) and (https://risteys.finregistry.fi/endpoints/E4_DM2), respectively. The summary statistics of glycemic traits are available from the MAGIC (https://www.magicinvestigators.org).
https://gwas.mrcieu.ac.uk/datasets/?gwas_id__icontains=met-d
